Literature DB >> 2122242

International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/1. Mutational events in the etiology of arteriosclerotic plaques.

A Penn1.   

Abstract

The arteriosclerotic plaque is the lesion most often associated with cardiovascular disease, which is the leading cause of death in North America and Western Europe. Plaques are composed of cells (mostly smooth muscle cells but also macrophages and some lymphocytes) and formed elements (cellular debris, collagen, elastin, glycosaminoglycans, lipid droplets, cholesterol crystals and sometimes calcium deposits). Proliferation of smooth muscle cells is essential to plaque formation and development. Most theories of plaque development have viewed this proliferation as a secondary event following an initiating stimulus (e.g., endothelial injury). According to this view, the proliferating smooth muscle cells are otherwise identical to the large number of non-proliferating smooth muscle cells in the artery wall. The 'monoclonal' hypothesis of plaque formation presents a fundamentally different view; namely, that the cell proliferation critical to plaque development follows the stable transformation of smooth muscle cells and that the plaques can therefore be viewed as benign smooth muscle cell tumors of the artery wall. Environmental agents, including viruses and chemicals that have been previously associated with cell transformation and tumorigenesis may therefore also contribute directly to plaque development. Data are provided from in vivo and in vitro studies in support of this proposition. Evidence is also presented that in standardized assays human and animal plaque DNAs elicit responses similar to those elicited by tumor DNAs. Thus, both plaque formation and tumorigenesis may share common mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122242     DOI: 10.1016/0165-1110(90)90003-t

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

1.  Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.

Authors:  M C Cornelis; A El-Sohemy; H Campos
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

2.  Arsenite inhibits Ras-dependent activation of ERK but activates ERK in the presence of oncogenic Ras in baboon vascular smooth muscle cells.

Authors:  G Daum; J Pham; J Deou
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

3.  Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the myc protooncogene.

Authors:  J L Parkes; R R Cardell; F C Hubbard; D Hubbard; A Meltzer; A Penn
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

4.  Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice.

Authors:  Adam C Straub; Donna B Stolz; Harina Vin; Mark A Ross; Nicole V Soucy; Linda R Klei; Aaron Barchowsky
Journal:  Toxicol Appl Pharmacol       Date:  2006-10-24       Impact factor: 4.219

5.  Modulation of myocardin function by the ubiquitin E3 ligase UBR5.

Authors:  Guoqing Hu; Xiaobo Wang; Darren N Saunders; Michelle Henderson; Amanda J Russell; B Paul Herring; Jiliang Zhou
Journal:  J Biol Chem       Date:  2010-02-18       Impact factor: 5.157

6.  The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation.

Authors:  Xiaobo Wang; Guoqing Hu; Xiangwei Gao; Yong Wang; Wei Zhang; Erin Yund Harmon; Xu Zhi; Zhengping Xu; Michelle R Lennartz; Margarida Barroso; Mohamed Trebak; Ceshi Chen; Jiliang Zhou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-23       Impact factor: 8.311

Review 7.  Potential role of polycyclic aromatic hydrocarbons as mediators of cardiovascular effects from combustion particles.

Authors:  Jørn A Holme; Bendik C Brinchmann; Magne Refsnes; Marit Låg; Johan Øvrevik
Journal:  Environ Health       Date:  2019-08-22       Impact factor: 5.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.